Evolysse Form and Evolysse Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse collection, are officially launching on Friday, April 18, 2025.
Evolus received U.S. Food and Drug Administration approval for Evolysse Form and Evolysse Smooth, for the treatment of nasolabial folds, in February 2025.
To support the introduction, Evolus will host a national Evolus Academy webcast for healthcare practitioners on April 18. The company has already begun an early experience program by sending product to more than 1000 key opinion leaders (KOLs), clinical investigators, and practices.
“With the introduction of Evolysse, we are bringing together the fastest-growing toxin in the category with the first new innovation in HA technology in over a decade,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “This is more than a product launch, it is the introduction of differentiated injectable HA gels that are grounded in clinical science and designed to meet the evolving needs of consumers seeking natural-looking results. By pairing this innovative Cold-X™ technology with the commercial strength we’ve built with Jeuveau®, we are well-positioned to expand our leadership with a differentiated injectable portfolio.”
John Fezza, MD, an Oculofacial Plastic Surgeon, adds, “With over 30 years of experience in the aesthetics industry, I’m excited to integrate Evolysse into my practice. These products represent the next generation of injectable HA gels, scientifically driven, delivering natural-looking results, and backed by a strong safety profile. Evolysse™ provides a new level of confidence when treating patients who are concerned about looking overdone or unnatural. It’s exactly what my patients have been asking for.”
